Log In
BCIQ
Print this Print this
 

Huntexil, pridopidine (formerly ACR16)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionSmall molecule sigma-1 receptor agonist
Molecular Target Sigma-1 receptor
Mechanism of ActionSigma-1 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHuntington's disease (HD)
Indication DetailsTreat Huntington's disease (HD); Treat symptoms of Huntington's disease (HD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$26.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/01/2012

Undisclosed

$26.1M

Undisclosed

Get a free BioCentury trial today